La catena delle opzioni mostra i dati chiave delle opzioni azionarie di ProKidney a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per ProKidney..

ProKidney (NASDAQ:PROK) Azioni, Catena delle Opzioni

ProKidney

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Elevate,Healthcare,With,Ai,Technology,Services.virtual,Health,Care,Analytics,Empower

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

PROK

RDNT

TCMD

RSI ai minimi e quotazioni in calo: quali aziende del settore medico potrebbero presto rialzarsi e offrire interessanti opportunità?

Occasioni nel settore sanitario: 3 titoli pronti per un rimbalzo

ProKidney Corp. - Class A Ordinary Shares

ProKidney Corp

Press Releases

Kuehn Law Encourages Investors of ProKidney Corp. to Contact Law Firm

Earnings

ProKidney Reports Full Year 2024 Financial Results and Business Highlights

ProKidney Reports First Quarter 2025 Financial Results and Business Highlights

ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware

Health Care

ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025

ADC Therapeutics

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Benitec Biopharma

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences

enGene Holdings

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Gossamer Bio

I-MAB

Inhibrx Biosciences

Invivyd

Jade Biosciences

Kamada

Keros Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Monopar Therapeutics

Neurogene

Ocugen

PureTech Health plc - American Depositary Shares

PureTech Health

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Solid Biosciences

Verastem

XOMA Royalty

Guggenheim

Citigroup

B of A Securities

Jefferies

Comments

ProKidney

ProKidney (PROK) Opzioni

ProKidney (NASDAQ:PROK) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO